There is great expectation in the Pharmaceutical Industry that the era of personalised medicine will deliver safer and more effective treatments (Jørgensen & Winther, 2009). This promise is made possible by the emergence of new technologies and data acquisition platforms that can generate enormous amounts of patient-level biomarker data to characterise biological processes and explain response to treatment.